Topping Off: IMV Immunovaccine shares continue to gain. See protected notices we led with this past week for TCR Network. |
Immunovaccine’s brisk trading of shares this April close comes ahead of a presumed $200 million licensing deal and perhaps more for the Nova Scotia laboratory.
The presumptions are here. The science is in Halifax.
[Today-Friday, the stock is rising 8 percent to a fresh high of $1.09 on the IMMVF scale. NASDAQ listing is near.] Such licensing arrangements involve payments to the owner of an oil-based drug-delivery system, in this case DepoVax with Survivac for treating ovarian cancer, HPV-linked cancers of neck, shoulders and throat, possibly Zika virus, malaria, pesky lymphomas and other infectious and rare or not-so-rare people killers.
All of the science is well displayed at the Immunovaccine home site and in several papers. Also: our own TCR Network reports distributed privately. This is year 12 for IMV and its approximtely 10-person laboratory and transactional CEO, Frederic Ors. http://thomcalandra.com/halifax-lab-in-10th-year-of-immunological-cures/
I added more shares of IMV/IMMVF this morning [Friday] and now own more than 200,000 of them. Licensing deals usually involve big pharma-cos: IMV already is involved with several in human trials, including Merck and Incyte. Prevously On TCR:
Immunovaccine — clinical test results coming from this immunotherapy company with a DepoVax delivery system, and possible partnerships with major drug companies and license-holders of select cancer-battling (hopefully) compounds, I believe will make global news — possibly on treating ovarian cancer. Good cheap science with good safe science.
Also: respiratory syncytial viruses. IMV is seeing above-par immunogenicity for its protein-antigen combinations using low doses.
Cheap, safe, and apparently longer lasting than any clinical candidates thus far for immunolgical compounds to treat cancer, viruses and follow-on conditions from some infectious diseases, DepoVax-Survivac injections with big-pharma compounds are turning heads after 12 years of lab work.
Look at the one-year and longer DepoVax human data across several applications: nearly 100 percents sccess at stopping tumor progression or lengthening, and at the very least maintaining original antibody levels. My understanding of all this comes from non-insider discussions with IMV execs nd board members and what anyone can find out looking at IMV’s extensive list of possible event triggers on its web site and in discussions with outside medical and pharma specialists … and large IMV shareholders. IMV/IMMVF is based in Halifax, Canada. Much insider-exec buying of shares.
I just received Immunovaccine’s annual general meeting proxy, Look at the share ownership by two of the founders: Albert Scardino and Wade Dawe.
“No guarantees, but licensing deals with mid-sized pharmaceutical companies can start at $300 million,” says Mr. Ors.
Keep one eye (not two) on Inovio, another immuno-developer. As Inovio‘s flogged, promoted and pushy INO (USA ticker) shares decline, and they will, IMV’s will rise. Once again, our two-year thesis.
It’s $1.05 USD share price today for IMMVF. Monday and Tuesday May 1 & May 2 will see continued brisk trading of IMV shares. Breakthrough news on clinical trials and fresh posters will come at San Diego’s BIO conference in June and later this year. Private materials making the case for IMV’s science have been available to TCR Network.
RHINOMED: I talked with Michael Johnson at RhinoMed on his Melbourne office phone Friday morning. The 1-for-10 consolidation will happen any day now. I think the tiny-co with the sleep managing deviced will become an “analog” leader in nasal passage therapies for breathing, sleeping, exercising, medicating … long list. RhinoMed can be a 20x candidate after the share consolidation shows the world what the company, with sales of its simple devices at drug stores in the USA, Canada, Australia, and elsewehere, can add to an already mounting bottom line. As in cash and a tiny “burn” of perhaps $100,000 Australian per quarter. Michael will be in NYC, New Jersey, Orlando, Chicago in the coming week. I own about 1.2 million RNO shares (pre-consolidation and sounds like a lot but comes to about $18 … USD total investment).
Pages: 1 2